Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIOB · Entity 2247 | EVP, Chief Operating Officer | September 06, 2024 | September 10, 2024 |
| Insight Molecular Diagnostics Inc.IMDX · Entity 6631 | Director | July 01, 2026 | July 07, 2026 |
| PRECIGEN, INC.XON · Entity 4356 | Chief Operating Officer | November 13, 2017 | November 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 06, 2024 · Filed September 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 7,559.4501 |
Ending reported balance
After 2024-09-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-06 · Exercise / conversion · Acquired 3,000 · Balance 10,559.4501 Row 2 · 2024-09-06 · Sale · Disposed 3,000 · Balance 7,559.4501 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $299.24 · Expires 2029-04-29 | Direct | 0 |
Reported balance
After 2024-09-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-06 · Exercise / conversion · Disposed 3,000 · Balance 0 F1: The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2019, which was the first anniversary of the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2019, which was the first anniversary of the date on which the option was granted.
Insight Molecular Diagnostics Inc.
Report date July 01, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 58,752 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Tax withholding · Disposed 7,700 · Balance 58,752 F1: The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.
PRECIGEN, INC.
Report date November 13, 2017 · Filed November 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2017-11-13 transaction · row 1
1 source rowRow 1 · 2017-11-13 · Purchase · Acquired 2,000 · Balance 4,000 F1: The price reported in Column 4 is a weighted average price of shares purchased in multiple transactions. The reporting person undertakes to provide to Intrexon Corporation ("Intrexon"), any security holder of Intrexon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price of shares purchased in multiple transactions. The reporting person undertakes to provide to Intrexon Corporation ("Intrexon"), any security holder of Intrexon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 7, 2026 00:38 UTC | Insight Molecular Diagnostics Inc. IMDX · Entity 6631 | Tax withholdingCommon Stock, no par value | 7,700 | $5.69 | $43,813.00 |
DisclosureSEC source: 0001493152-26-032233 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,752 F1 · security: The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 22:22 UTC | Insight Molecular Diagnostics Inc. IMDX · Entity 6631 | GrantCommon Stock, no par value | 26,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-028754 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,452 F1 · security: The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service from the date of grant until the vesting date. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:05 UTC | Insight Molecular Diagnostics Inc. IMDX · Entity 6631 | GrantCommon Stock, no par value | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-017787 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,509 F1 · security: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 18:05 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $299.24 | $0.00 |
DisclosureSEC source: 0001062993-24-016386 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2029-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2019, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 18:05 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 3,000 | $329.94 | $989,815.20 |
DisclosureSEC source: 0001062993-24-016386 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,559.4501 Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 18:05 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,000 | $299.24 | $897,720.00 |
DisclosureSEC source: 0001062993-24-016386 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,559.4501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 903 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · derivative · entry 12 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 458 | $337.32 | $154,492.56 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 8 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,559.4501 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 903 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 7 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,017.4501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 633 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · derivative · entry 11 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633 Underlying: Bio-Rad A Common Stock · 633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 2,532 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 2,532 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 867 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · derivative · entry 10 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,735 Underlying: Bio-Rad A Common Stock · 867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 3,469 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 3,469 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,252 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · derivative · entry 9 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,756 Underlying: Bio-Rad A Common Stock · 1,252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2023, the reporting person was granted 5,008 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2023, the reporting person was granted 5,008 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 321 | $337.32 | $108,279.72 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 6 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,114.4501 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 633 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 5 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,435.4501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 440 | $337.32 | $148,420.80 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 4 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,802.4501 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 867 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,242.4501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 635 | $337.32 | $214,198.20 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,375.4501 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016169 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,010.4501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 38.5620 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2024. Read SEC document |
| July 01, 2024 Filed Jul 4, 2024 01:00 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 30,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001493152-24-026273 · ownership.xml · derivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 21:53 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009082 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 21:53 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 357 | $277.11 | $98,928.27 |
DisclosureSEC source: 0001062993-24-009082 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,719.8881 Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 21:53 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009082 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,076.8881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 9.7660 and 27.5220 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2023 and 03/31/2024, respectively. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,891 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006221 · form4.xml · derivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,891 Underlying: Bio-Rad A Common Stock · 5,891 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 903 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · derivative · entry 10 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903 Underlying: Bio-Rad A Common Stock · 903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 448 | $394.60 | $176,780.80 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · nonDerivative · entry 6 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,039.6001 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 903 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · nonDerivative · entry 5 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,487.6001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 633 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · derivative · entry 9 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,266 Underlying: Bio-Rad A Common Stock · 633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 2,532 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 2,532 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 867 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · derivative · entry 8 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,602 Underlying: Bio-Rad A Common Stock · 867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 3,469 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 3,469 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 5,008 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · derivative · entry 7 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,008 Underlying: Bio-Rad A Common Stock · 5,008 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 279 | $394.60 | $110,093.40 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · nonDerivative · entry 4 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,584.6001 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 633 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · nonDerivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863.6001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 430 | $394.60 | $169,678.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,230.6001 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 18:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 867 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017654 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660.6001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 26.9850 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023. Read SEC document |
| June 23, 2023 Filed Jun 28, 2023 01:30 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 90,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001493152-23-022669 · ownership.xml · derivative · entry 2 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-06-23 F2 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 23, 2023 Filed Jun 28, 2023 01:30 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock, no par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-022669 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,170 F1 · security: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| April 29, 2023 Filed May 1, 2023 16:51 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-009749 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2023 Filed May 1, 2023 16:51 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 346 | $450.79 | $155,973.34 |
DisclosureSEC source: 0001062993-23-009749 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,766.6151 Read SEC document |
| April 29, 2023 Filed May 1, 2023 16:51 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-009749 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,112.6151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 8.8470 and 20.7590 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2022 and 03/31/2023, respectively. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 902 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019282 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,806 Underlying: Bio-Rad A Common Stock · 902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 448 | $478.32 | $214,287.36 |
DisclosureSEC source: 0001062993-22-019282 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,083.0091 Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 902 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019282 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,531.0091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:56 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 633 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019194 · form4.xml · derivative · entry 4 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899 Underlying: Bio-Rad A Common Stock · 633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 2,532 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 2,532 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:56 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 3,469 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019194 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,469 Underlying: Bio-Rad A Common Stock · 3,469 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:56 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 314 | $486.25 | $152,682.50 |
DisclosureSEC source: 0001062993-22-019194 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629.0091 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:56 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 633 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019194 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,943.0091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 16.8874 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2022. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 12:00 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 20,000 | $0.87 | $17,400.00 |
DisclosureSEC source: 0001493152-22-023524 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,170 Read SEC document |
| August 15, 2022 Filed Aug 18, 2022 00:21 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001493152-22-023385 · ownership.xml · derivative · entry 2 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-08-15 F2 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| August 15, 2022 Filed Aug 18, 2022 00:21 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock, no par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-023385 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,170 F1 · security: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 24, 2022 Filed Jul 19, 2022 20:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019822 · ownership.xml · derivative · entry 2 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Stock Units vested on June 24, 2022. F1 · derivative.expiration_date: The Restricted Stock Units vested on June 24, 2022. Read SEC document |
| June 24, 2022 Filed Jul 19, 2022 20:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019822 · ownership.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.